Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables (2016 - 2025)

Historic Receivables for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $11.0 million.

  • Intellia Therapeutics' Receivables rose 2480.23% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 2480.23%. This contributed to the annual value of $8.5 million for FY2024, which is 7726.13% down from last year.
  • Intellia Therapeutics' Receivables amounted to $11.0 million in Q3 2025, which was up 2480.23% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Receivables peaked at $37.5 million during Q4 2023, and registered a low of $1.8 million during Q1 2022.
  • For the 5-year period, Intellia Therapeutics' Receivables averaged around $9.5 million, with its median value being $6.5 million (2023).
  • In the last 5 years, Intellia Therapeutics' Receivables plummeted by 9102.81% in 2021 and then skyrocketed by 59776.45% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Receivables stood at $2.1 million in 2021, then surged by 151.9% to $5.4 million in 2022, then surged by 597.76% to $37.5 million in 2023, then tumbled by 77.26% to $8.5 million in 2024, then increased by 29.74% to $11.0 million in 2025.
  • Its Receivables stands at $11.0 million for Q3 2025, versus $11.4 million for Q2 2025 and $10.5 million for Q1 2025.